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Abstract: 
In light of the large-scale expansion of human periosteum derived stem cells for the 
treatment of large bone defects, a multiplate bioreactor system (Pall Integrity Xpansion) in 
combination with an integrated holographic imaging platform (Ovizio iLine S microscope) 
was evaluated. The culture process was quantitatively characterized by imaging data, 
metabolite concentrations and a breakdown of the cell recovery fractions. The resulting cell 
quality was assessed based on the minimal criteria for mesenchymal stem cells, including 
viability on cell culture plastic, identity markers and tri-lineage differentiation potential. 
Additionally, an in vivo bone forming potency assay was used in an ectopic mice model that 
resulted in compelling bone formation (11.6% ± 3.1% and 12.8% ± 3.3% for the bioreactor 
and control tissue culture flask condition respectively). Therefore it was shown that the 
bioreactor is able to produce large quantities of cells, while maintaining satisfactory cell 
quality. 
 
  
1 Introduction 
Currently, more than 1300 active clinical trials are reported using cell-based therapies to 
treat a wide variety of indications ranging from cardiovascular to neurological disorders, as 
well as skeletal disorders [1]. Around 380 of these trials use mesenchymal stem cells (MSCs) 
as the therapeutic cell source. While most applications require between 107–109 MSCs for a 
single dose [2,3], cell expansion is traditionally carried out in 2D (monolayer) static culture 
set ups (e.g. tissue culture flasks or cell factories) that require extensive manual open-
process interventions for media exchange and cell harvest. The high labor and infrastructure 
costs associated with these techniques hamper the socio-economic viability of the therapy 
after clinical translation. In combination with a lack of suitable potency assays related to the 
in vivo biological response of the cells [4], the relatively low number of successful clinical 
translations of cell-based therapies are mainly attributed to the challenges associated with 
the production of the required cell numbers, while at the same time assure high and 
reproducible cell quality [3,5–7]. This highlights the rising need to develop and incorporate 
automated bioreactor systems for large-scale production of progenitor cells for clinical 
applications.  
Additionally, due to the inherent complexity of biologic processes, traditional cell culture 
processes that were designed by a rule-of-thumb approach are difficult to adapt to an 
efficient and robust clinical process that is able to deliver an efficacious product to every 
single patient. The full potential of cell-based therapies will therefore only be able to be 
harnessed by a cell culture process that is standardized, scalable and able to deliver clinically 
relevant cell numbers, while at the same time assure potent biological functionality in vivo 
[8–10]. Recently, considerable effort is placed in developing such processes based on 
bioreactor systems, for example in the form of hollow fiber bioreactors [11,12] and wave-
rocking bioreactors for microcarrier-based expansion [13].  
In this work, a monitored multiplate bioreactor (Pall Integrity® Xpansion™ equipped with 
Ovizio iLine S microscope) was evaluated as a platform for the clinical-scale expansion of 
human periosteum derived stem cells (hPDCs) and its ability to monitor the cell expansion 
process was evaluated. hPDCs are a promising source of progenitor cells for the treatment of 
skeletal defects. During the natural bone healing process they have been shown to be the 
main contributors to tissue regeneration [14,15], while after ex vivo expansion, they have 
been recently shown to possess improved bone forming capabilities compared to other MSC 
sources (e.g. bone marrow and synovium) when seeded on calcium phosphate carriers [16]. 
Using this multilayered bioreactor, limited changes to the classical planar cell culture process 
are required as opposed to, for example, microcarrier-based cell expansion where complex 
process variables need to be optimized (e.g. material/surface properties, 
hydrodynamics)[17]. This is due to the fact that cells are seeded and cultured on a 2D cell 
culture surface similar to the conditions found in standard tissue culture flasks. In addition, 
the extensive quantitative bioreactor read-outs that can be obtained at-line, such as 
dissolved oxygen concentrations, pH and microscopic images, can be used to improve the 
control over the expansion process, ultimately leading to a more robust in vivo outcome 
[18]. 
The objective of this work is the development of a clinical scale bioreactor process for the 
expansion of hPDCs in the Xpansion bioreactor. The advantages of thorough process 
monitoring are illustrated and the synergy between the multiplate bioreactor and the 
mounted microscope is highlighted. In addition to the standard post-harvest in vitro cell 
characterization assays that were performed, an in vivo potency assay was implemented 
which is often lacking in bioprocess studies relevant to cell therapy applications.  
2 Materials and methods 
The experimental outline consists of 4 consecutive phases: (1) a pre-culture phase in tissue 
culture flasks in order to reach the amount of cells required for bioreactor seeding, (2) 
7 days of bioreactor expansion with continuous monitoring of multiple process parameters, 
(3) cell harvest and concentration, and (4) post-harvest cell characterization in which the 
cells from the bioreactor are compared to a target quality profile of cells cultured in parallel 
in standard tissue culture flasks (Figure 1). The in vitro cell characterization is inspired on the 
International Society for Cellular Therapy (ISCT) minimal criteria for MSCs [19], 
supplemented with a bone forming assay in order to assess the in vivo potency of the cells 
[20]. The bioreactor process was first evaluated and adapted to the needs of hPDCs in three 
small scale process development runs in the Xpansion-10. In a following phase the process 
was translated to a larger scale bioreactor (Xpansion-50) that resembles the clinical-scale 
production.  
2.1 Flask-based hPDC culture 
hPDCs were isolated from 4 different donors by means of enzymatic digestion of a periost 
biopsy as described by Eyckmans et al. [21]. Procedures were approved by the ethical 
committee for Human Medical Research (KU Leuven) and patient informed consent forms 
were obtained. The isolated cells were cultured in T25 flasks for the first passage in standard 
culture medium consisting of high glucose GlutaMAXTM Dulbecco’s modified Eagle’s medium 
(Life Technologies, Merelbeke, Belgium) supplemented with 10% irradiated fetal bovine 
serum (FBS; HyClone, Cramlington, UK), 1% sodium pyruvate (Invitrogen) and 1% antibiotic–
antimycotic (100 units/ml penicillin, 100 mg/ml streptomycin, and 0.25 mg/ml amphotericin 
B; Invitrogen). Cells were further cultured in T175 flasks with a seeding density of 5 700 
cells/cm2 and sub-cultured at ± 80% confluence. At passage 3, the cells from the 4 different 
donors were pooled all together and further expanded in T175 flasks up to passage 7 
(approximately 12 total population doublings). hPDCs generally maintain linear growth 
curves for over 30 population doublings [22]. At all passages, cells were harvested by 
trypsinization for 10 min with TrypLE Express (Invitrogen). 
2.2 Bioreactor based hPDC culture 
The Pall Life Sciences Xpansion™® (Pall Life Sciences, Brussels, Belgium) is a multiplate 
bioreactor that houses from 10 to 200 hydrophilized polystyrene plates of ± 612 cm2 each 
(Figure 2). The plates are tightly packed around a central aeration column, that provides gas 
exchange controlled by an active gas flow controller. Based on the integrated temperature, 
dissolved oxygen and pH sensors, the culture conditions can be monitored and controlled 
[23,24]. Additionally, by making use of the holographic Ovizio iLine S microscope (Ovizio 
Imaging Systems, Brussels, Belgium), the cells inside the bioreactor can be visualized and 
critical process parameters such as cell density and morphological features can be non-
invasively extracted in a quantitative way. 
After passage 7, the cells were transferred to the multiplate bioreactor with a total culture 
surface of 6 125cm2 (Xpansion-10) for the first 3 process development runs, and later to the 
Xpansion-50 with a total culture surface of 30 600 cm2. The bioreactor and culture medium 
were pre-heated overnight in the incubator at 37°C in order to prevent gas bubble formation 
during filling. For each bioreactor run, at least 3 control tissue culture flasks were taken 
along as positive control for the cell expansion procedure and subsequent cell 
characterization. The control tissue culture flasks were seeded at the same initial seeding 
density as the bioreactors in order to compare growth kinetics. The inoculation densities of 
the bioreactor were corrected for the void volumes in the bioreactor (i.e. central aeration 
column and headspace) according to the manufacturer’s instructions to assure a similar 
density on the bioreactor plates as in the control tissue culture flasks. For the Xpansion-50 
bioreactor it was calculated that a little more than 85% of the cells from the inoculation 
volume will settle on the bioreactor plates. The seeding volume in the Xpansion-10 was 1.7 
L, in the Xpansion-50 the volume was 5.7 L. After transferring the inoculation volume to the 
bioreactor, the bioreactor was incubated at 37°C for 7 days in parallel with the control flasks. 
The automated controller was only allowed to engage 9 hours after seeding in order to allow 
sufficient time for cell attachment, as the controller actions are accompanied by mixing of 
the medium. 
The cells grown in the bioreactor were harvested after 7 days, together with the control 
flasks. First, after draining the culture medium, the bioreactor was rinsed once with pre-
heated PBS (one bioreactor volume). A pre-heated diluted TryplE concentration was used (5 
times diluted in PBS), supplemented with EDTA (ethylenediaminetetraacetic acid) to a final 
concentration of 1.8 mM to harvest the cells from the bioreactor plates. This adapted 
harvest solution was optimized in T25 flasks based on a novel method that allows for the 
real-time quantification of the harvest kinetics by an imaging algorithm and the 
determination of cell yield and viability (Viazzi et al., in preparation/press). For the 
bioreactor harvest a diluted harvest solution was preferred over the standard TryplE harvest 
as the final harvest volume is relatively large (5.6 L for the Xpansion-50, 21.9 L for example 
for the Xpansion-200). Therefore, to facilitate the downstream processing it was not chosen 
to neutralize this volume, as this would increase the volume even more, and spin down the 
harvested cells in the diluted TryplE solution.  
Right after adding the harvesting solution to the bioreactor, the vessel was moved to the 
microscope platform in order to visually assess cell detachment from the plates. In parallel, 
one of the control flasks was harvested with the same adapted harvest solution in order to 
assess the effectiveness of the solution and to have a reference for the required incubation 
time. Once all cells were circular and started to detach from the polystyrene plates, the 
vessel was mechanically shaken on the Xpansion harvest station to completely detach the 
cells. The cell suspension was subsequently drained from the bioreactor under constant 
agitation in order to keep the cells in suspension. The harvested volume was then reduced 
by spinning down the non-neutralized cell-containing harvest solution. As a final step, the 
bioreactor was rinsed with PBS and placed under the Ovizio microscope again to check the 
harvest efficiency. 
As the cell harvest in the Xpansion bioreactor is a critical step in the process, the cell 
recovery efficiency was identified after each step in the entire process. As shown in section 
3.1, cell density at the day of harvest was determined by the Ovizio microscope. This density 
was used as the reference (100%). Viable cells were counted on samples from the waste 
medium drained from the bioreactor at day 7, from the 1st PBS rinse, the non-neutralized 
harvest volume, the suspension after volume reduction and the 2nd PBS rinse after harvest 
based on trypan blue exclusion. 
2.2.1 Monitoring and control of cellular environment in the bioreactor 
Temperature, pH and dissolved oxygen concentration were continuously monitored at the 
top plate of the bioreactor. The pH and oxygen concentration were actively controlled by the 
injection of gasses (CO2, O2 and N2) through the central aeration column. pH was set-up to 
be controlled between 7.25 and 7.56 for the runs in the Xpansion-10 bioreactor, and 
between 7.42 and 7.56 for the Xpansion-50. These set points were based on observed 
culture conditions in standard tissue culture flasks. The dissolved oxygen concentration was 
set-up to be higher than 40% air saturation, with the main goal of preventing anoxic 
conditions in the bioreactor. The mixing of the culture medium is effectuated by a magnetic 
impeller at the bottom of the bioreactor. The magnetic stirrer was automatically engaged 
(0.5 mm/s) during injection of gasses for pH or O2 control to assure sufficient mixing. When 
the gas controller was idle, the agitation rate in the Xpansion-10 runs was set up in a way 
that it would exhaustively mix the bioreactor volume at least every 4 hours (i.e a mixing time 
of 20 min every 4 hours according to the manufacturers specifications). In the Xpansion-50 
bioreactor continuous agitation was applied resulting at low linear speed (0.5 mm/s, 40 rpm) 
in order to mix the medium as much as possible. The bioreactor medium and control flask 
were sampled daily and lactate concentrations were determined immediately (Arkray 
Lactate Pro). The bioreactor was sampled via the sampling line, only after the bioreactor 
volume was mixed for at least 20 minutes. Samples for lactate, glucose, glutamine and 
glutamate were also measured on frozen samples using a YSI 2950 Biochemistry Analyzer 
(Ankersmid M&C, Wilrijk, Belgium).  
2.2.2 Metabolite analysis 
An estimation of the oxygen consumption rate during the exponential growth phase in the 
Xpansion-50 bioreactor run was determined based on the measured oxygen concentration in 
the bioreactor. As the perceived oxygen uptake rate is influenced by the supply of external 
gasses, only oxygen concentration data was used during time points at which the controller 
was inactive. Within the exponential growth phase 7 timeframes were selected with a length 
of 4 hours (i.e. approximately equally spread out between day 1.5 and day 5), that were 
located at least 2 hours after gas injection or controller disconnection during imaging. The 4 
hour timeframe was considered to have sufficient samples for a robust consumption rate 
calculation, while it is short enough to assume constant cell numbers. The midpoint of the 4h 
timeframe was used for a linear interpolation between 2 daily cell density measurements 
from the Ovizio microscope (see section 2.2.3). Based on the interpolated cell number, a cell 
specific oxygen consumption rate was calculated. This oxygen consumption estimation 
assumed a closed system, since the contact surface of the filter on the gas vent is negligible 
compared to the 5.7L volume of the Xpansion-50 bioreactor. 
The glucose and lactate consumption rates were calculated between consecutive daily 
samples and normalized to cell number to obtain cell specific consumption and production 
rates using the equation:                    , where      (mM) is the change in 
metabolite concentration during the time period   (days) and      (cells) the average 
number of cells during the same period. The metabolic ratios (qMET1/qMET2) are calculated by 
dividing the average consumption or production rates of the same time period. 
2.2.3 Process monitoring by holographic imaging 
Cell growth in the bioreactor was monitored on a daily basis by disconnecting the gas and 
sensor lines, taking the bioreactor out of the incubator and placing it under the Ovizio 
microscope. The microscope set-up allows taking multiple holographic images per plate, and 
this for the upper ±10 plates. The OsOne software (Ovizio, Brussels, Belgium) allows to semi-
automatically quantify the number of cells, the cell density on the plates and is able to 
provide specific morphological features per cell.  
2.3 Post-harvest cell characterization 
2.3.1 Growth kinetics 
Growth kinetics of the harvested cells was monitored via the PrestoBlue metabolic assay 
(Life Technologies, Merelbeke, Belgium) as described in Sonnaert et al. [25]. Cells were 
seeded at 5700 cells/cm2 in a 12-well plate. Every day the normal growth medium was 
replaced by a 10% v/v PrestoBlue reagent supplemented growth medium. After 1 hour 
incubation (37°C, 95% RH, 5% CO2) the metabolic activity in the well was quantified by 
fluorescence measurements (Bio-Tek SynergyTM HT, Bad Friedrichshall, Germany) with an 
excitation wavelength of 540nm and an emission wavelength of 590nm on 100ml 
supernatant in a 96-well plate. A higher metabolic activity is indicated by higher fluorescent 
values. 
2.3.2 3-lineage in vitro differentiation potential 
Chondrogenic differentiation of the cultured hPDCs was assessed in a micro-mass assay as 
described earlier [14]. In short, 2x105 cells were re-suspended in 10 µL culture medium and 
seeded as micro-mass in a 24-well plate. After 2 hours incubation (37°C, 5% CO2, 95% RH) 0.5 
ml standard culture medium was added. After 24 hours, the medium was replaced by 
chondrogenic medium consisting of DMEM/F12 (Life Technologies), 2% FBS, 1% antibiotic–
antimycotic, 1% ITS Premix (Corning), 100nM dexamethasone (Sigma), 10µM Y27632 (Axon 
Medchem), 50µg/ml ascorbic acid, 40µg/ml proline and 10ng/ml recombinant human 
transforming growth factor-β1 (Preprotech, London, UK). The chondrogenic medium was 
refreshed every other day. Micro-masses in normal culture medium were taken along as 
negative control. After 7 days of chondrogenic induction the micro-masses were fixed for 1 
hour in ice cold methanol and stained at room temperature for 1 hour with a 0.1% Alcian 
Blue solution in 0.1M HCL at pH 1.2.  
Osteogenic differentiation was assessed by seeding the cells in 24-well plates at a density of 
4 500 cells/cm2 in 0.5 ml standard culture medium. After 48 hours the medium was replaced 
by standard culture medium supplemented with 100 mM dexamethasone, 50 µg/ml ascorbic 
acid and 10 mM β-glycerolphosphate. The medium was refreshed 3 times per week for 21 
days. Samples in standard culture medium were used as negative control. Cells were fixed 
prior to analysis in ice cold methanol for 1 hour and afterwards stained with a 2% Alizarin 
Red S solution in Baxter water.  
Adipogenic differentiation was investigated by seeding the cultured hPDCs in 24-well plates 
at a density of 1x104 cells/cm2 in 0.5 mL standard culture medium. After 24 hours the 
medium was replaced by adipogenic medium consisting of αMEM (Life Technologies) 
supplemented with 10% FBS, 1% antibiotic–antimycotic, 1 µM Dexamethasone, 10 µg/ml 
human insulin (Sigma), 100 µM indomethacin (Sigma) and 25 µM 3-isobutyl-1-
methylxanthine (Sigma). Medium was refreshed 3 times per week. At day 14, cells were 
fixed in 10% formaldehyde for 20 minutes, rinsed shortly with 60% isopropanol and stained 
with Oil Red O. 
2.3.3 MSC phenotyping 
The expression of typical MSC cluster of differentiation (CD) markers [19] and lack of 
expression for the haematopoietic markers on the harvested cells was evaluated based on a 
hMSC Phenotyping Kit (Miltenyi Biotec). The CD marker combinations used are CD90+-FITC 
(clone DG3), CD73+-APC (clone AD2), CD105+-PE (clone 43A4E1), CD14- (clone 
TUK4)/CD20- (clone LT20.B4)/CD34- (clone AC136)/CD45- (clone 5BI)-PerCP. The non-specific 
isotype control stain panel included mIgG1-FITC, mIgG1-PE, mIgG1-APC, mIgG1-PerCP (clone 
IS5-21F5) and mIgG2-PerCP (clone S43.10). 6x105 cells per condition were washed in 
blocking solution (1%FBS in PBS) and the concentrated cell suspension was re-suspended in 
100 µL of stain solution (1:11 antibody dilution in blocking solution) for 10 minutes at 4°C. 
After washing the aliquots with blocking solution again, the samples were analyzed on a 
FACSCanto (BD Biosciences, San Jose, Ca, USA) equipped with FACSDiva acquisition software 
(BD Biosciences). 10 000 total events were acquired. Data analysis was done in FlowJo V10 
(TreeStar Inc., Ashland, OR, USA). 
2.3.4 In vivo bone forming potency assay and quantification 
One million cells in a total volume of 35 µL culture medium were seeded on 35 mm3 clinical 
grade orthopaedic 3D matrices composed of calcium phosphate particles in an open collagen 
network (NuOss, ACE Surgical Supply Co.,Inc, Hannover, Germany) in triplicates per 
condition. The scaffolds were incubated overnight (37°C, 5%CO2, RH95%) before ectopic 
implantation on the back of nude mice (NMRI-nu/nu). Eight weeks later the mice were 
sacrificed, the scaffolds were retrieved, fixed overnight in 4% paraformaldehyde and 
preserved in PBS before scanning by X-ray computed tomography. All animal experiments 
and procedures were approved by the Animal Ethics Committee (KU Leuven). Animals were 
housed in accordance with the guidelines of the Animal Research Center of KU Leuven. 
The volume of newly formed bone after 8 weeks of in vivo implantation was determined by 
nanofocus X-ray computed tomography (nanoCT) performed on a Phoenix NanoTom S 
(GE Measurement and Control) system equipped with a diamond-tungsten target and 
0.5 mm aluminum filter. The applied scan settings were 60 kV X-ray voltage, 210 mA current, 
500 ms exposure time, a frame averaging of 1 and image skip of 0. Images were 
reconstructed with Phoenix Datos|x CT software (GE Measurement and Control) and a 3 µm 
voxel size. The quantification of the bone volume was based on a 2-level automatic Otsu 
segmentation algorithm. The match of the segmented areas was confirmed visually for each 
sample. In case of mismatch, manual segmentation levels were determined based on the 
greyscale histogram of the whole sample. All image processing was performed in CTAn 
(Bruker micro-CT). 
2.4 Statistical analysis 
Statistical analysis was performed using Matlab 2013a (The MathWorks, Inc., Natick, MA). 
Independent groups were compared by unpaired Student’s t-tests, and considered 
statistically significant in case P-value <0.05. Error bars in figures represent standard 
deviation of mean. 
3 Results and discussion 
3.1 Monitoring cell growth 
An example of a holographic image taken at the third plate from the top in the Xpansion-50 
bioreactor at the final day of culture (day 7) where cells were at ±80% confluence can be 
found in Figure 3A. Figure 3B shows the same image after analysis by the OsOne software, 
where cell perimeter is indicated and counted cells are identified. The software was able to 
match the cell densities with a visual assessment of the original image. The microscope was 
therefore used to quantitatively monitor the bioreactor processes throughout the whole 
culture period in terms of cell number and homogeneity of cell distribution. Figure 3C shows 
the average cell density over the 7 days culture period, based on the analysis of daily 
pictures of the top 5 plates of the Xpansion-50 bioreactor. 
The Xpansion-50 bioreactor was seeded with a total of 160 million cells in a 5.7 L seeding 
volume. Taking into account the void volume in the bioreactor this would theoretically result 
in a seeding density of 4 400 cells/cm2. The seeding density of the bioreactor was verified by 
the microscope (based on pictures at day 0 in Figure 3C) and was found to be around 4 500 
cells/cm2. This was close to the theoretical seeding density and matched the density used to 
seed the control flasks (4 400 cells/cm2) (Figure 3D, day 0). Additionally, referring to the 
relatively small standard deviation on the microscope-based cell density estimate at day 0 in 
the bioreactor (Figure 3C), it can be stated that a homogeneous seeding density was 
achieved, which is important for an efficient cell expansion process. Over the 7 day culture 
period, a sigmoidal cell growth can be perceived with a 2 day lag period followed by an 
exponential growth phase, as is common after sub-culturing the hPDCs. The stagnation of 
growth at day 7 indicates confluence of the plates.  
The cell density at the day of harvest was estimated to be around 17 500 cells/cm2 in the 
bioreactor based on the data generated by the microscope. Given the 4 500 cells/cm2 and 7 
day culture period, this corresponds to a 86h population doubling time of the cells. In the 
control flasks, the resulting cell density was 17 300 cells/cm2 based on manual cell counts 
after harvesting the flasks with TrypLE (corresponding to a 85h population doubling time of 
the cells). It can therefore be concluded that the growth kinetics and the level of confluence 
in the bioreactor and the control tissue culture flasks are equivalent. Population doubling 
times are comparable to the standard hPDC culture, however relatively high compared to 
typical values for MSCs in literature [26–28]. It was demonstrated before that the 
continuous agitation in the bioreactor, resulting in continuous exposure of the cells to 
laminar flow (0.5 mm/s) would not damage cells, since hPDCs have been cultured regularly 
in perfusion bioreactor at more intense flow conditions [29,30]. 
3.2 Monitoring metabolic activity 
Dissolved oxygen tension and pH were continuously monitored over the 7 days of culture, 
and are shown in Figure 4. The short interruptions in the bioreactor sensor data are due to 
disconnecting the bioreactor from the controller in order to image the plates with the 
microscope. Small fluctuations in air saturation were caused by the injected air during pH 
control actions. Over the 7 day culture period the pH drops slightly. The dissolved oxygen 
concentration dropped gradually due to cell consumption (until around day 3 in the 
Xpansion-10 runs, until day 5 for the Xpansion-50). Afterwards, the controller took action to 
maintain the dissolved concentration above the 40% air saturation set. The resulting average 
cell specific oxygen consumption rate during the exponential growth phase was 1.08  ± 0.22 
x 10-17mol.s-1.cell-1. Although cell type and culture method dependent, this consumption rate 
is around one order of magnitude smaller compared to previously reported values in 
literature for MSCs [31,32]. When compared to a previous study on hPDCs specifically, i.e. a 
flow through perfusion bioreactor culture on 3D scaffolds [33], the oxygen consumption rate 
per cell (1.1 x 10-17 mol.s-1.cell-1) was very close to the amount perceived in this study.  
Lactate, glucose, glutamine and glutamate concentrations were measured in daily medium 
samples both from the Xpansion-50 bioreactor and the control flask (Figure 5). In the 
Xpansion-10 bioreactor runs only lactate was measured, these production profiles showed 
similar trends as the Xpansion-50 data (data not shown). Metabolite concentrations in the 
Xpansion bioreactor were similar compared to the tissue flask condition over the 7 days 
culture (Figure 5). However, slightly higher lactate concentrations were registered in the 
culture flask condition. The lactate concentration, both in the bioreactor and the control 
flasks, remained well below the growth inhibitory level for MSCs (35.4mM) determined by 
Shop et al. (2009) [34]. Glucose consumption rates and lactate production rates are shown in 
Table 1. As cell number quantification in the tissue flasks was done only at day 7 of culture, 
the cell specific consumption rates and production rates in table 1 for the control flasks are 
referring only to the last day in culture. The average cell specific rates for the bioreactor 
could be determined daily based on the cell density estimates from the microscope. These 
rates were relatively constant over the culture period and an average is given in Table 1. For 
the sake of comparison with the control flasks, the rate at day 7 is also given for the 
bioreactor. The perceived lactate production and glucose consumption rates are in line with 
literature on other MSCs [35].  
The ratio of produced lactate over consumed glucose (qLAC/qGLUC), which is cell number 
independent, was equal to 2.54 ± 0.39 and 1.82 ± 0.37 for the tissue culture flask condition 
and bioreactor condition respectively, and remained stable over the whole culture. Although 
not significantly different, this qLAC/qGLUC ratio suggests that the energy production from 
glucose was more efficient in the bioreactor culture compared to the culture flask, and 
potentially indicates a different utilization of carbon sources. This difference might have 
been caused by the continuous mixing in the bioreactor that prevents built-up of diffusion 
gradients above the cell surface. The ratio of consumed oxygen over consumed glucose 
(qO2/qGLUC) in the bioreactor was equal to 0.11. This relatively low qO2/qGLUC ratio in non-
hypoxic culture conditions, combined with the relatively high qLAC/qGLUC ratio suggested 
aerobic glycolysis as the preferred metabolic pathway during hPDC expansion [36,37]. 
Glutamate concentrations remained quasi constant, while the glutamine concentration 
needed around 2 days to reach a ±2 mmol/L level (Figure 5). The same trend was followed in 
both conditions, however the glutamine concentration was generally lower in the culture 
flask condition. Quantification of cell specific glutamine consumption rate is difficult in 
Glutamax (a more stable L-glutamine L-alanine dipeptide which gets hydrolyzed by cell 
activity and is a therefore a steady source of glutamine, but which cannot be quantified by 
the medium analyzer) supplemented media and without information on ammonia 
concentrations (the end product of natural glutamine decay). 
3.3 Bioreactor harvest and downstream processing 
The average total incubation time in the adapted harvest solution for the Xpansion was 38 ± 
7 minutes. This was ±2 times longer than what was required for cell detachment in T175 
flasks. It is hypothesized that the increase in required incubation time was due to a less 
effective first PBS rinse in the bioreactor, where the serum remnants might have partially 
inhibited the proteolytic trypLE reaction.  
Table 2 indicates the recovered fraction of viable cells per step in the harvest process. The 
data is based on analysis of the third run in the Xpansion-10 bioreactor as this harvest 
procedure was the most exhaustively analyzed and had the furthest developed procedure. 
The cell count in the waste medium and 1st PBS rinse amounted up to nearly 10% of the total 
amount of the cells present on the plates at the time of harvest. However, these steps are 
generally also present in the harvest procedure in the traditional flask based process (not 
quantified in this study) and were therefore irrelevant regarding cell yield. More important, 
± 82% of the cells were found back in the non-neutralized harvest suspension. Cells within 
this fraction were collected by centrifugation (290 rcf) and used subsequently for post-
harvest cell characterization. Another ± 6% of the cells was found in the 2nd PBS rinse and on 
the plates at the end of the harvest procedure. The total of all fractions add up to ± 104%. 
This overestimation is probably due to the fact that two different counting methods were 
used (manual cell counting and the Ovizio microscope based counts). Additionally, although 
prevented by all means possible, counting and sampling errors are inevitable in such large 
volumes with in some cases relatively low cell numbers present due to the high dilution 
factors. 
The final step in the harvest procedure was the volume reduction by centrifugation. Taking 
into account the ± 76% centrifugation efficiency gained in the non-neutralized harvesting 
suspension, in total a ± 63% final recovery efficiency of the cells present on the plates of the 
bioreactor was recorded in the third process development run in the Xpansion-10. Although 
a similar final cell density on the plates was reached in the Xpansion-50 and the same 
harvesting procedure was used, the final recovery efficiency in the Xpansion-50 bioreactor 
was around 45%. This reflects a final yield of 7 900 cells/cm2. So, despite the high cell density 
gained in the Xpansion-50 bioreactor growth, many cells were lost in the downstream 
processing for this specific run. While the final density here was almost 4 times the density 
as reported for hepatic progenitor cells in the Xpansion-200 (difficult to compare due to the 
different cell types) [23], more effort is required on the downstream processing. Based on 
the recovery efficiencies listed here, most gain can be made mainly by improving the 
centrifugation efficiency. Exploration of alternative volume reduction bioprocesses such as 
the use of continuous centrifugation [38] or filtration systems [39] could also provide 
solution for a higher cell recovery. In light of this, it should be noted that in case of the 
Xpansion-50 it was the first time this research group was handling these sizes of harvest 
volumes. The authors are therefore convinced that by further development of the volume 
reduction and centrifugation process, the total cell yield can be improved significantly.  
3.4 Post-harvest cell characterization  
After each bioreactor run, the harvested cells were subjected to a standard quality check 
and compared to the target quality profile as derived from the tissue culture flask condition. 
3.4.1 Growth kinetics of harvested cells 
Figure 6 represents the average growth curve (n=4) over 7 days as determined by the 
PrestoBlue assay for the harvested cells after being re-seeded in 12-well plates. Growth 
kinetics of the harvested cells were similar for all bioreactor runs and up to day 7 no 
significant difference between the bioreactor condition and tissue culture flask condition 
was found. The lack of increased lag phase during initial culture days for the cells harvested 
from the bioreactor suggests that environmental stress during the bioreactor harvest 
procedure did not induce cell damage [38].  
3.4.2 In vitro 3-lineage differentiation 
After each bioreactor run the in vitro 3-lineage differentiation potential of the cells was 
assessed. Both cells from the bioreactor and tissue culture flasks were able to differentiate 
towards the adipogenic, osteogenic and chondrogenic lineage as shown in Figure 7. Both in 
bioreactor run 3 and run 4, the in vitro chondrogenic differentiation was impaired compared 
to the tissue culture flask condition (Figure 7, bottom). It is hypothesized that this loss of in 
vitro chondrogenic potential was caused by an increased TrypLE exposure time as all other 
conditions were kept constant. It should be noted that in the case of the culture process 
being up-scaled with a flask or cell factory-based strategy the holding times of the cells will 
undoubtedly also increase. More importantly, the impaired in vitro chondrogenesis in run 3 
and 4 did not influence the outcome of the in vivo results, nor the CD marker expression 
(section 3.3.4 and 3.3.3 respectively). 
3.4.3 MSC phenotype 
Figure 8 on the left side indicates the simultaneous positivity for the standard MSC markers 
CD73, CD90 and CD105 for cells from the bioreactor and the control flask. On the right side 
the percentage of cells that are positive for at least one CD marker from the pool of 
hematopoietic markers CD45, CD20, CD14, CD34 are shown. Based on the flow cytometry 
data, cells harvested from the bioreactor showed a clear MSC like phenotype, that was close 
to identical the control flasks. Little variation between the different runs was perceived. 
3.4.4 In vivo bone forming potential 
The in vivo performance for cells is a crucial aspect in the cell characterization process. As 
discussed by Bianco et al. [20], the in vitro assays that are suggested by the ISCT [19], and 
which were shown here (3.3.1-3: adherence to plastic, in vitro 3-lineage differentiation and 
(lack of) expression of certain CD markers) are of value as means to standardize MSC 
characterization. However, these assays are not necessarily reflecting the in vivo potency of 
the cells for specific indications. Therefore, in this work, an assay with a known mechanism 
of action was chosen, in order to assess the bone forming activity of the harvested cells in 
vivo [40,41]. The amount of newly formed bone as quantified by nanoCT was normalized to 
the available volume in the scaffold (i.e. not taking into account the space occupied by the 
remaining calcium phosphate grains within the scaffold, see indications on Figure 9). All 
samples in both conditions resulted consistently in compelling ectopic bone formation in 
vivo. As quantified by the nanoCT analysis the average newly formed bone volume was 
11.6% ± 3.1% and 12.8% ± 3.3% for the bioreactor and tissue culture flask respectively. 
Based on the boxplot it can be seen that the spread on the data is similar for both 
conditions, but the quartiles are closer for the bioreactor conditions. No statistical difference 
was found between the two conditions and the perceived quantities of newly formed bone 
corresponded to what was reported earlier in literature [40]. It is interesting to note that 
while cells from run 3 and 4 showed impaired chondrogenic differentiation potential (section 
3.4.2), they were still able to form a compelling amount of bone in vivo. This stresses the 
need for potency assays that are able to assess relevant biological functions and illustrates a 
limitation of the ISCT minimal criteria [42]. However, as the time and resources required for 
in vivo assays are considerable, more cost-effective assays should be developed that might 
for example look at the secretome (e.g. trophic factors) [43]. 
Although technically challenging, upscaling planar tissue culture technology is attractive for 
autologous tissue culture strategies (or small batch sizes of allogeneic cells) since relatively 
small changes to the standard culture conditions are required. In addition, the Pall Xpansion 
bioreactor specifically adds a significant level of automation and control to the planar culture 
process, while at the same time it is scalable between 6120 cm2 (xpansion-10) and 122 400 
cm2 (Xpansion-200). Based on the cell densities achieved in the expansion-50, the theoretical 
cell yield for hPDCs would be around 2x109 cells in the Xpansion-200 (for bone marrow 
MSCs, which are smaller in size, this would be more close to 3x109 at a harvest density of 25 
000 cells/cm2). Although this accounts already for a considerable cell yield, allogeneic cell 
therapy strategies will benefit from microcarrier or suspension culture technologies, as more 
favorable economies of scale can be reached due to the much larger culture surface to 
volume ratio [3,7,8,44]. Discussing which culture system is better in terms of cell quality is 
challenging as this depends heavily on specific cell type, clinical indication and bioprocess 
design. Recent studies have shown that hMSC expansion on planar adherent surfaces could 
lead to gradual loss of their therapeutic potency with altered immune modulatory 
properties, low survival rate post transplantation, and changes in their secretory profile and 
therapeutic potential due to an increasing senescent subpopulation [45–47]. However, 
similar effects could also occur during suspension culture under certain process conditions 
[48,49].  
4 Conclusion 
In conclusion, the Xpansion bioreactor enabled the production of large amounts of 
progenitor cells, while maintaining equivalent cell quality compared to the standard flask-
based culture. Importantly, it was shown that these cells retained their regenerative 
potential resulting in compelling in vivo bone formation. The efficiency of the culture process 
for this specific cells type reached a bottleneck at the downstream level, in particular during 
cell recovery. However, in addition to the integrated sensors and medium sampling 
possibilities of the bioreactor, the transparent stacked plate design in combination with the 
microscope offered excellent monitoring capabilities allowing to exactly pinpoint the root 
cause of the bottleneck. Consequently, future efforts will be directed towards optimizing the 
recovery efficiency during downstream processing. The large-scale production of progenitor 
cells under quantitative real-time process monitoring provides a tool for the translation to 
robust clinical implementation and facilitates the regulatory trajectory. 
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Tables: 
 
 Bioreactor Tissue culture flask 
Day 7 Average Day 7 Average 
Glucose consumption 
(pmol.day-1cell-1) 
5.1 8.1 ± 0.34 3.4 n.a. 
Lactate production 
(pmol.day-1cell-1) 
9.2 13.9 ± 0.58 7.9 n.a. 
Ratio qLAC/qGLUC 1.8 1.8 ± 0.37 2.3 2.5 ± 0.39 
Ratio qO2/qGLUC n.a. 0.11 n.a. n.a. 
Table 1: Cell specific glucose consumption rates, lactate production rates and metabolic 
ratios. 
 
Step in harvest process % of cells counted  
Cell count on plates after 7 days of culture (*) 100% = reference 
Cell count in waste medium 3.20% 
Cell count in 1st PBS rinse 6.4% 
Cell count in non-neutralized harvest suspension 82.4% 
Cell count in 2nd PBS rinse 6.1% 
Cell count of cells on plate after rinse (*) 6.2% 
Total 104.2% 
Table 2: Summary of recovered viable cell fraction per step during the harvest process 
relative to the optically determined number of cells on the day of harvest. The (*) indicates 
fractions determined by the microscope, the other fractions are based on cell counts. 
  
List of figures and figure captions: 
Figure 1: Overview of the general experimental outline with an initial tissue culture flask-
based pre-culture phase, followed by the Xpansion bioreactor culture. During the bioreactor 
culture the cell growth was monitored based on daily images from the Ovizio iLine S 
microscope and samples of the medium. Three standard tissue culture flasks were cultured 
in parallel as a positive control. Immediately after cell harvest and cell concentration the cell 
characterisation was initiated, including among others, an in vivo bone forming potency 
assay. 
Figure 2: Illustration of the bioreactor design. A) Bioreactor housing from bottom to top: 
bottom plate that fits on a magnetic stirrer which is installed in the incubator, magnetic 
impeller that drives the medium flow between the plates, cylindrical housing in which the 
polystyrene plates are tightly packed around the central aeration column, top plate with the 
connection to the gas flow rate controller, sensor probes, sampling lines and vent. The tubes 
for filling and draining the bioreactor are connected to the bottom plate of the bioreactor 
and shown on the sides. Note that the height of the housing is adapted to the number of 
plates for the different bioreactor scales. B) Stack of polystyrene plates inside the bioreactor 
housing. The red arrows indicate the medium recirculation through radial channels in the 
plates and through the aeration column. C) Close-up of central aeration column that 
provides gas exchange with the culture medium. D) Close-up of side view on three plates 
where the radial channels allow medium perfusion over the cells. The available culture 
surface per plate is 612 cm2 and the headspace between each plate is 1.6 mm, and this for 
every scale of the bioreactor. E) Close-up of bottom plate where the culture medium is 
recirculated by the impeller through the radial channels in the plates towards the top of the 
bioreactor. Illustration courtesy of Pall Corporation. 
Figure 3: (A) Holographic image at the third plate from the top in the Xpansion-50 bioreactor 
(B) Same image as in A with cell quantifications and signature data by OsOne software (C) 
Growth curve of hPDCs in Xpansion-50 bioreactor based on daily microscope-based 
quantification of the cell density (D) Cell density quantification in the control flasks based on 
manual counting after TryplE harvest. All error bars represent standard deviation of the 
mean. 
Figure 4: On-line dissolved oxygen concentration (top) and pH (bottom) monitoring. A lower 
threshold of 40% air saturation was chosen, while for the pH a range between 7.25 to 7.56, 
and 7.42 to 7.56 was chosen for the Xpansion-10 and Xpansion-50 runs respectively. 
Figure 5: Accumulated metabolite concentration in bioreactor and tissue culture flask (TCF) 
over the 7 day culture process. (A) Glucose and lactate, (B) glutamine and glutamate, 
continuous lines indicate bioreactor data, dashed lines indicate tissue culture flask data. 
Error bars represent standard deviation of the mean. 
Figure 6: PrestoBlue-based average (n=4) growth curve of re-plated harvested cells in a 12-
well plate. Error bars represent standard deviation of the mean. 
Figure 7: Representative images of the in vitro 3-lineage differentiation assay for cells from 
the bioreactor, tissue culture flask and a negative control in normal medium shown in the 
left, middle and right column respectively. (top) Oil Red O staining after 2 weeks of 
adipogenic differentiation. (middle) Alizarin red staining after 3 weeks osteogenic 
differentiation. (bottom) Alcian Blue staining after 1 week chondrogenic differentiation in 
micro-mass culture. 
Figure 8: Percentage of simultaneous positivity for common MSC markers (CD73, CD90 and 
CD105) and common hematopoietic markers (CD45, CD20, CD14, CD34). Error bars 
represent standard deviation of the mean. 
Figure 9: (top and bottom left) Slides from the reconstructed nanoCT images, ”b” indicating 
remaining calcium phosphate grains from the implanted scaffold, “*” indicating newly 
formed bone tissue. The negative control consists of an implanted scaffold without cells. 
(bottom right) Box plot of the newly formed bone volume normalized to the available 
scaffold volume as determined by nanoCT imaging. Horizontal lines indicate first quartile, 
median and third quartile, whiskers indicate minimum and maximum, asterisk indicates 
average.  
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